American Journal of Health Behavior,
Год журнала:
2025,
Номер
49(1), С. 14 - 22
Опубликована: Янв. 31, 2025
Background:
Patients
suffering
from
Alzheimer's
disease
usually
experience
different
neuroanatomical
changes
such
as
depression,
apathy
and
irritability.
Other
cognitive
behaviours
found
are
linked
with
impairment
well
disease.
Cardiovascular
issues
also
to
be
common
among
the
patients,
Aim
of
Study:
This
study
aims
assess
health
behavior
their
association
within
progression
impairment.
For
this
purpose,
hyperintensities
in
white
matter
(WHM)
were
observed.
Methodology:
In
current
longitudinal
study,
grey
atrophy
WMH
changes,
is
observed
cohort.
regard,
120
participants
included
while
310
220
control
groups
incorporated.
Neuroanatomical
determined
by
using
Neuropsychiatric
Inventory,
which
classified
into
apathy,
affective
hyperactivity
subsyndromes.
Automatic
technique
was
used
for
measuring
WMH.
Results:
The
results
obtained
linear
mixed-effects
models
show
that
has
a
significant
other
subsyndromes
groups.
Significant
context
vascular
risks.
Conclusion:
identified
major
contributor
NPS
moderate
ACS Chemical Neuroscience,
Год журнала:
2025,
Номер
16(2), С. 111 - 127
Опубликована: Янв. 6, 2025
Alzheimer's
disease
(AD)
and
non-AD
tauopathies
are
dominant
public
health
issues
driven
by
several
factors,
especially
in
the
aging
population.
The
discovery
of
first-generation
radiotracers,
including
[18F]FDDNP,
[11C]PBB3,
[18F]flortaucipir,
[18F]THK
series,
for
vivo
detection
has
marked
a
significant
breakthrough
fields
neuroscience
radiopharmaceuticals,
creating
robust
new
category
labeled
compounds:
tau
positron
emission
tomography
(PET)
tracers.
Subsequently,
other
PET
tracers
with
improved
binding
properties
have
been
developed
using
various
chemical
scaffolds
to
target
three-repeat/four-repeat
(3R/4R)
folds
AD.
In
2020,
[18F]flortaucipir
was
approved
U.S.
Food
Drug
Administration
imaging
pathology
adult
patients
cognitive
deficits
undergoing
evaluation
Despite
remarkable
progress
development
AD
tracers,
agents
rare
(4R
[predominantly
expressing
4R
isoform],
involved
progressive
supranuclear
palsy,
corticobasal
degeneration,
argyrophilic
grain
disease,
globular
glial
tauopathy,
3R
such
as
Pick's
disease)
remain
substantially
underdeveloped.
this
review,
we
discuss
recent
tracer
development,
particular
emphasis
on
clinically
validated
their
potential
use
tauopathies.
Additionally,
highlight
critical
need
further
specifically
designed
tauopathies,
an
area
that
remains
significantly
underexplored
despite
its
importance
advancing
understanding
diagnosis
these
disorders.
This
review
analyzes
the
role
of
TNF-α
and
its
increase
in
biological
fluids
mild
cognitive
impairment,
Alzheimer’s
disease
(AD).
The
potential
inhibition
with
pharmacological
strategies
paves
way
for
preventing
AD
improving
function
people
at
risk
dementia.
We
conducted
a
narrative
to
characterize
evidence
relation
involvement
possible
therapeutic
inhibition.
Several
studies
report
that
patients
RA
systemic
inflammatory
diseases
treated
blocking
agents
reduce
probability
emerging
dementia
compared
general
population.
Animal
model
also
showed
interesting
results
are
discussed.
An
increasing
amount
basic
scientific
data
clinical
underscore
importance
processes
subsequent
glial
activation
pathogenesis
AD.
targeted
therapy
is
biologically
plausible
approach
cognition
preservation
further
trials
necessary
investigate
benefits
populations
developing
The Egyptian Journal of Neurology Psychiatry and Neurosurgery,
Год журнала:
2024,
Номер
60(1)
Опубликована: Июнь 14, 2024
Abstract
Alzheimer’s
disease
(AD)
is
a
neurodegenerative
condition
that
causes
cognitive
decline,
memory
loss,
and
reduced
personal
autonomy.
The
pathology
of
AD
involves
the
aggregation
abnormal
brain
proteins,
specifically
beta-amyloid
plaques
tau
tangles,
disrupting
neuronal
communication
leading
to
loss
cells.
Aducanumab,
monoclonal
antibody,
demonstrates
promise
in
clinical
trials
by
selectively
binding
aggregated
amyloid-beta,
notable
decrease
plaque
burden
potential
benefits.
However,
regulatory
approval
for
aducanumab
remains
controversial.
Lecanemab
donanemab
are
recent
additions
AD’s
treatment
landscape,
both
targeting
amyloid-beta.
shares
similarities
with
its
mechanism
action,
while
employs
distinct
approach
specific
truncated
form
Positive
outcomes
have
been
observed
early-stage
drugs,
demonstrating
reduction
amyloid-beta
plaques.
While
aducanumab’s
offers
hope
treatment,
ongoing
studies
on
lecanemab
imperative
comprehensive
understanding
their
modification.
Here,
we
show
this
review
treatments,
focus
primary
action
ultimately
giving
broader
insight
topic.
emphasizes
necessity
long-term
efficacy
safety
data
assess
overall
impact
these
drugs
decline
functional
future
researchers
endeavor.
In
conclusion,
development
antibodies
represents
significant
stride
demanding
further
investigation
ascertain
true
role
therapeutic
arsenal
challenging
condition.
Metabolic Brain Disease,
Год журнала:
2025,
Номер
40(2)
Опубликована: Фев. 1, 2025
The
central
nervous
system
(CNS)
is
immune-privileged
by
several
immuno-modulators
as
interleukins
(ILs).
ILs
are
cytokines
secreted
immune
cells
for
cell-cell
signaling
communications
and
affect
the
functions
of
CNS.
were
reported
to
orchestrate
different
molecular
cellular
mechanisms
both
physiological
pathological
events,
through
overproduction
or
over-expression
their
receptors.
They
interact
with
numerous
receptors
mediating
pro-inflammatory
and/or
anti-inflammatory
actions.
Interleukins
have
been
implicated
participate
in
neurodegenerative
diseases.
play
a
critical
role
Alzheimer's
disease
(AD)
pathology
which
characterized
over-production
ILs.
These
may
aggravate
neurodegeneration,
addition
contribution
detrimental
oxidative
stress,
excitotoxicity.
However,
recent
research
on
relation
between
AD
revealed
major
discrepancies.
Most
shown
pro-
roles
experimental
settings
models.
interactions
shared
pathways
also
add
difficulty
drawing
solid
conclusions.
In
addition,
targeting
has
not
yielded
consistent
results.
repeated
failures
therapeutic
drugs
treating
necessitate
search
novel
agents
multiple
pathology.
this
context,
understanding
throughout
progression
interaction
other
systems
brain
provide
promising
targets
prevention
treatment
AD.
Alzheimer s & Dementia,
Год журнала:
2025,
Номер
21(3)
Опубликована: Март 1, 2025
Abstract
Neuropsychiatric
symptoms
(NPS)
are
common
throughout
the
Alzheimer's
disease
(AD)
continuum
and
profoundly
affect
patients,
caregivers,
health‐care
systems.
This
review
synthesizes
key
research
presented
in
2022
2023
Association
International
Society
to
Advance
Research
Treatment
Syndromes–Professional
Interest
Area
(NPS‐PIA)
Year‐In‐Reviews,
emphasizing
six
critical
areas:
(1)
diversity
disparities,
(2)
diagnostic
frameworks,
(3)
neurobiology
of
NPS,
(4)
NPS
as
a
marker,
(5)
impact
COVID‐19,
(6)
interventions.
accelerates
AD
progression,
increases
functional
decline,
diminishes
quality
life,
heightens
caregiver
burden
institutionalization
rates.
Current
treatments
primarily
rely
on
psychotropics,
which
offer
limited
efficacy
raise
safety
concerns.
aims
inform
clinicians
researchers
about
recent
advancements
while
identifying
gaps
for
future
studies
improve
outcomes
individuals
with
AD.
Highlights
disease–related
neuropsychiatric
has
rapidly
increased,
indicating
heightened
interest.
Key
areas
include:
diversity,
diagnostics,
markers,
COVID‐19
impact,
treatments.
A
road
map
studies,
based
research,
is
provided.
includes
considerations
study
applicability
validity.
International Journal of Molecular Sciences,
Год журнала:
2024,
Номер
25(5), С. 2645 - 2645
Опубликована: Фев. 24, 2024
The
clinical
features
and
pathophysiology
of
neuropsychiatric
symptoms
(NPSs)
in
dementia
have
been
extensively
studied.
However,
the
genetic
architecture
underlying
neurobiological
mechanisms
NPSs
at
preclinical
stages
cognitive
decline
Alzheimer's
disease
(AD)
remain
largely
unknown.
Mild
behavioral
impairment
(MBI)
represents
an
at-risk
state
for
incident
is
defined
by
emergence
persistent
among
non-demented
individuals
later
life.
These
include
affective
dysregulation,
decreased
motivation,
impulse
dyscontrol,
abnormal
perception
thought
content,
social
inappropriateness.
Accumulating
evidence
has
recently
begun
to
shed
more
light
on
background
MBI,
focusing
its
potential
association
with
factors
related
AD.
Apolipoprotein
E
(APOE)
genotype
MS4A
locus
associated
ZCWPW1
inappropriateness
psychosis,
BIN1
EPHA1
NME8
apathy.
between
MBI
polygenic
risk
scores
(PRSs)
terms
AD
also
explored.
Potential
implicated
neuroinflammation,
synaptic
dysfunction,
epigenetic
modifications,
oxidative
stress
responses,
proteosomal
impairment,
immune
responses.
In
this
review,
we
summarize
critically
discuss
available
emphasis
AD,
aiming
gain
insights
into
mechanisms,
which
till
now
unexplored.
addition,
propose
future
areas
research
emerging
field,
aim
better
understand
molecular
links
decline.
Antioxidants,
Год журнала:
2024,
Номер
13(9), С. 1062 - 1062
Опубликована: Авг. 30, 2024
Neurodegenerative
diseases
encompass
a
spectrum
of
disorders
marked
by
the
progressive
degeneration
structure
and
function
nervous
system.
These
conditions,
including
Parkinson's
disease
(PD),
Alzheimer's
(AD),
Huntington's
(HD),
Amyotrophic
lateral
sclerosis
(ALS),
Multiple
(MS),
often
lead
to
severe
cognitive
motor
deficits.
A
critical
component
neurodegenerative
pathologies
is
imbalance
between
pro-oxidant
antioxidant
mechanisms,
culminating
in
oxidative
stress.
The
brain's
high
oxygen
consumption
lipid-rich
environment
make
it
particularly
vulnerable
damage.
Pro-oxidants
such
as
reactive
nitrogen
species
(RNS)
(ROS)
are
continuously
generated
during
normal
metabolism,
counteracted
enzymatic
non-enzymatic
defenses.
In
diseases,
this
balance
disrupted,
leading
neuronal
This
systematic
review
explores
roles
stress,
gut
microbiota,
epigenetic
modifications
aiming
elucidate
interplay
these
factors
identify
potential
therapeutic
strategies.
We
conducted
comprehensive
search
articles
published
2024
across
major
databases,
focusing
on
studies
examining
relationships
redox
homeostasis,
changes
neurodegeneration.
total
161
were
included,
comprising
clinical
trials,
observational
studies,
experimental
research.
Our
findings
reveal
that
stress
plays
central
role
pathogenesis
with
microbiota
composition
significantly
influencing
balance.
Specific
bacterial
taxa
markers
identified
modulators
suggesting
novel
avenues
for
intervention.
Moreover,
recent
evidence
from
human
animal
supports
emerging
concept
targeting
homeostasis
through
therapies.
Future
research
should
focus
validating
targets
settings
exploring
personalized
medicine
strategies
based
individual
profiles.
